Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA – Nasdaq
Wolcott Daily |
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Nasdaq NEW YORK and CLEVELAND, Feb. 08, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today … Abeona’s Sanfilippo Gene Therapy Data Produces Encouraging ResultsPharmaceutical Processing Abeona’s gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%Seeking Alpha Why Abeona Therapeutics Jumped 14% on WednesdayMadison.com The Ledger Gazette –Wolcott Daily –Zacks –Zacks all 51 news articles » |
Wolcott Daily |
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
GlobeNewswire (press release) NEW YORK and CLEVELAND, Feb. 08, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today … Abeona’s Sanfilippo Gene Therapy Data Produces Encouraging ResultsPharmaceutical Processing Abeona’s gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%Seeking Alpha Why Abeona Therapeutics Jumped 14% on WednesdayMadison.com The Ledger Gazette –Wolcott Daily –StockNewsTimes –Zacks all 51 news articles » |
EurekAlert (press release) |
Molecular ‘magnets’ could improve cancer immunotherapy
EurekAlert (press release) “It’s still early days, but attracting more cDC1 to tumours could be the basis of a new immunotherapy for cancer patients.” The team also showed that prostaglandin E2 (PGE2), a molecule produced by some cancer cells, suppresses Natural Killer cell … |
|
Immunotherapy in the Treatment of Follicular Lymphoma
OncLive Grzegorz S. Nowakowski, MD: I’d probably start by saying that if you look at follicular lymphoma, this should be the prime target for immunotherapy. We know about the role of the microenvironment in this disease; it has been extensively studied with … |